Eyegate Pharmaceuticals, Inc. Appoints Keith Maher, M.D. as A Class III Director
January 10, 2020 at 09:18 pm
Share
On January 10, 2020, the Board of Directors of EyeGate Pharmaceuticals, Inc. upon the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Keith Maher, M.D. as a Class III director of the company to fill the vacancy created by the previously disclosed resignation of Peter Greenleaf as a member of the Board. Dr. Maher’s appointment was effective as of January 10, 2020, and he will serve in office until the 2021 annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier resignation or removal. Keith Maher, M.D. has worked at Armistice Capital covering healthcare since 2019. From 2013 through 2018, Dr. Maher served as the North American healthcare analyst for Schroder Investment Management. Prior to joining Schroder, Dr. Maher held senior roles at Omega Advisors, Gracie Capital and Paramount BioCapital. Prior to joining Paramount, Dr. Maher was a Managing Director at Weiss, Peck & Greer (WPG) Investments. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher has served on the board of directors of Vaxart, Inc., a Nasdaq-listed clinical stage company developing tablet vaccines, since November 2019.
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).